Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
237.04
-0.49 (-0.21%)
At close: Jul 16, 2026, 4:00 PM EDT
239.85
+2.81 (1.19%)
Pre-market: Jul 17, 2026, 5:30 AM EDT
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $191.20M in the quarter ending March 31, 2026, with 57.42% growth. This brings the company's revenue in the last twelve months to $708.24M, up 63.88% year-over-year. In the year 2025, Axsome Therapeutics had annual revenue of $638.50M with 65.55% growth.
Revenue (ttm)
$708.24M
Revenue Growth
+63.88%
P/S Ratio
17.22
Revenue / Employee
$580,521
Employees
1,220
Market Cap
12.20B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 638.50M | 252.80M | 65.55% |
| Dec 31, 2024 | 385.69M | 115.09M | 42.53% |
| Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
| Dec 31, 2022 | 50.04M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.24B |
| Exelixis | 2.38B |
| Bio-Techne | 1.21B |
| Madrigal Pharmaceuticals | 1.13B |
| Arrowhead Pharmaceuticals | 622.01M |
| Krystal Biotech | 417.30M |
| Cytokinetics | 105.82M |
| ABIVAX Société Anonyme | 5.67M |
AXSM News
- 2 days ago - Axsome Therapeutics announces FDA acceptance of AXS-12 NDA - TheFly
- 2 days ago - Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy - GlobeNewsWire
- 3 days ago - Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10 - GlobeNewsWire
- 10 days ago - Axsome Therapeutics price target raised to $304 from $302 at RBC Capital - TheFly
- 10 days ago - Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD) - GlobeNewsWire
- 15 days ago - Why Axsome Stock Has Doubled In Nine Months - Forbes
- 21 days ago - Axsome Therapeutics doses first patient in FOCUS-3 trial - TheFly
- 21 days ago - Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) - GlobeNewsWire